Ibrutinib

Ibrutinib is an oral targeted anticancer medicine belonging to the Bruton’s tyrosine kinase (BTK) inhibitor class. It works by blocking BTK, an enzyme involved in B-cell receptor signalling that helps certain B lymphocytes survive, multiply, and migrate within the body. By inhibiting this pathway, ibrutinib can reduce the survival and activity of abnormal B cells associated with particular blood cancers. It is used in selected patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström’s macroglobulinaemia (WM), as well as in eligible patients with chronic graft-versus-host disease (cGVHD) under applicable regulatory approvals. The medicine is available in oral formulations, including capsules, tablets, and an oral suspension in the United States. Treatment may be given alone or alongside other medicines, depending on the disease, treatment history, and applicable prescribing guidance. Ibrutinib is clinically important because it targets a specific signalling pathway rather than directly attacking all rapidly dividing cells. However, it can cause significant adverse effects, including bleeding, infections, abnormal heart rhythms, high blood pressure, and reduced blood cell counts. Appropriate patient selection, medication review, laboratory testing, and ongoing clinical monitoring are essential during treatment.

Ibrutinib was developed as a targeted inhibitor of Bruton’s tyrosine kinase, a signalling protein important for the development, activation, and survival of B cells. The US Food and Drug Administration (FDA) granted its first approval in November 2013 for previously treated mantle cell lymphoma. Subsequent US approvals expanded its use to selected patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström’s macroglobulinaemia. The European Commission granted marketing authorisation for Imbruvica, the ibrutinib-containing medicine, on 21 October 2014 following a positive opinion from the European Medicines Agency (EMA). Regulatory indications have changed over time as additional clinical evidence became available and benefit-risk assessments were updated. In the United States, certain earlier indications, including mantle cell lymphoma and marginal zone lymphoma, were removed from the prescribing information in 2023. The current US prescribing information includes adult CLL/SLL, Waldenström’s macroglobulinaemia, and chronic graft-versus-host disease in adults and children aged one year and older after failure of one or more lines of systemic therapy. European indications differ in some respects and include specified uses in mantle cell lymphoma and CLL. Prescribers should consult the current local product information because approved indications and treatment combinations vary by jurisdiction.

Ibrutinib is used for selected blood cancers and immune-related complications according to the approved prescribing information in each country. In the United States, it is indicated for adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), including CLL/SLL with deletion of chromosome 17p, and for adults with Waldenström’s macroglobulinaemia. It is also approved for adults and children aged one year and older with chronic graft-versus-host disease after failure of one or more lines of systemic therapy. Depending on the indication and treatment plan, ibrutinib may be used alone or in combination with medicines such as rituximab, obinutuzumab, or bendamustine and rituximab. In the European Union, approved uses additionally include specified settings of mantle cell lymphoma, including relapsed or refractory disease and certain previously untreated patients eligible for autologous stem cell transplantation. Treatment selection depends on the disease subtype, previous therapies, genetic findings where relevant, other medical conditions, and local regulatory approval. Ibrutinib should be prescribed and supervised by a clinician experienced in treating the relevant condition.

Ibrutinib is administered orally as capsules, tablets, or an oral suspension, depending on the available formulation and approved indication. Under US prescribing information, the usual adult dose for CLL/SLL and Waldenström’s macroglobulinaemia is 420 mg once daily. For chronic graft-versus-host disease, the recommended dose is 420 mg once daily for patients aged 12 years and older and 240 mg/m² once daily, up to 420 mg, for children aged one to under 12 years. Dosing for other indications and combination regimens must follow the applicable local product information. Treatment is generally continued until disease progression, recurrence of the underlying malignancy where relevant, or unacceptable toxicity, depending on the indication. Capsules should be swallowed according to the product instructions, and tablets must not be cut, crushed, or chewed. Missed doses, dose reductions, temporary interruptions, and adjustments for liver impairment or interacting medicines should be managed according to prescribing guidance. Blood counts, liver function, blood pressure, cardiac symptoms, and signs of infection or bleeding should be monitored throughout treatment.

Common side effects of ibrutinib include diarrhoea, fatigue, muscle or joint pain, nausea, bruising, skin rash, fever, and upper respiratory tract infections. Some patients may develop reduced platelet counts, low neutrophil counts, anaemia, or other changes in blood cell counts. High blood pressure and minor bleeding, such as easy bruising or nosebleeds, may also occur. The frequency and severity of these effects vary according to the indication, treatment duration, other medicines, and individual health status. Supportive care, hydration, symptom management, laboratory monitoring, and appropriate dose adjustments can help manage adverse effects. Patients should report persistent diarrhoea, worsening fatigue, unusual bruising, fever, or symptoms that interfere with daily activities. Medical assessment is important because apparently mild symptoms can sometimes indicate a more serious complication.

Ibrutinib carries important risks, including major or potentially fatal bleeding, serious infections, cardiac arrhythmias such as atrial fibrillation, cardiac failure, hypertension, and significant reductions in blood cell counts. Cases of sudden cardiac death and serious liver injury have also been reported. Tumour lysis syndrome can occur in susceptible patients, particularly when treatment rapidly reduces a high burden of cancer cells. Secondary primary malignancies, including skin cancers and other cancers, have been reported. Ibrutinib can also cause fetal harm and should be avoided during pregnancy according to applicable prescribing guidance. Patients experiencing significant bleeding, chest pain, fainting, breathlessness, a rapid or irregular heartbeat, severe infection symptoms, jaundice, or other concerning symptoms require prompt medical evaluation. Treatment may need to be interrupted, reduced, or discontinued depending on the nature and severity of the event. Decisions about interruption around surgery or invasive procedures should be individualised according to bleeding risk and the prescribing information.

Before starting ibrutinib, clinicians should review the patient's medical history, bleeding risk, cardiovascular status, infection history, liver function, complete blood count, and all prescription medicines, over-the-counter products, and supplements. Particular caution is required in patients with previous bleeding disorders, atrial fibrillation, heart failure, uncontrolled hypertension, active infections, or significant liver impairment. Ibrutinib is metabolised mainly through the CYP3A pathway. Strong or moderate CYP3A inhibitors may increase drug exposure and toxicity, whereas strong CYP3A inducers may reduce exposure and treatment effectiveness. Anticoagulants, antiplatelet medicines, and non-steroidal anti-inflammatory drugs may increase bleeding risk and require careful review. Live vaccines should generally be avoided during treatment, and vaccination planning should follow current clinical guidance. Pregnancy prevention and breastfeeding advice should follow the relevant product information. Dose adjustment or avoidance may be necessary with certain interacting medicines or in severe hepatic impairment. Patients should not start or stop other medicines without consulting their treating clinician or pharmacist.

Prescribers should confirm the exact indication, disease subtype, prior treatment history, and applicable regulatory label before selecting an ibrutinib regimen. Obtain baseline blood counts, liver function tests, blood pressure measurements, and a cardiovascular assessment, with additional investigations guided by the patient's risk factors. Review CYP3A interactions carefully and assess the combined bleeding risk of anticoagulants, antiplatelet agents, and other medicines. Counsel patients to take ibrutinib consistently according to product instructions and to report bleeding, fever, palpitations, breathlessness, or signs of liver injury promptly. Establish a monitoring plan for blood counts, blood pressure, infections, cardiac symptoms, and treatment-related toxicities. For planned surgery or invasive procedures, coordinate any temporary treatment interruption with the prescribing specialist. Pharmacists should verify formulation-specific administration instructions, storage requirements, adherence, and dose adjustments following toxicity or changes in concomitant medicines. When ibrutinib is combined with other anticancer or immune-modifying therapies, coordinate monitoring and supportive care across the treatment team.